Study Reveals How People Talk To AI About Health
New research from Microsoft analyzes Copilot conversations to understand what kinds of health questions users ask AI and how this could affect response design.
Medtech Insight - April 21, 2026

Bayer Pledges Loyalty To Europe But Demands More Support
Europe’s legacy as a scientific powerhouse will belong very much in the past if it doesn’t keep pace with the US and China, the German group warns.
Scrip - April 21, 2026

Top 10 Drugs 2025: Keytruda Holds The Crown, But Tirzepatide Is Coming
The GLP-1 franchises of Eli Lilly and Novo Nordisk reshaped the leaderboard in 2025 while long-standing giants braced for looming patent cliffs.
Scrip - April 21, 2026

AstraZeneca’s Ultomiris Hits Interim Phase III Endpoint In IgAN, Eyes Accelerated Filings
Full results from the I CAN trial will show Ultomiris's long-term impact on kidney function as AstraZeneca looks to expedite its regulatory filings in IgAN.
Scrip - April 21, 2026

India’s Trademark Regime: Regulatory Gaps, Patient Safety Risks And ‘Criminal Contempt’
Novo Nordisk, GSK and Sanofi are among the leading companies that have tackled trademark infringement in India amid a siloed regulatory architecture. Legal experts weigh in on the goings on and point to the tough message from courts on ‘willful disobedience’ of injunctive relief.
Scrip - April 21, 2026

Stock Watch: Prospects For Peace Help J&J After Results Announcement
Many investor-friendly elements punctuated J&J’s first-quarter results but its stock price initially traded down. For once, it took geopolitical developments to give it a boost.
Scrip - April 21, 2026

Nektar Charts Rezpeg’s Late-Stage Development In Alopecia Areata On Long Term Phase II Data
The latest extension data positions Rezpeg for late-stage development, with upcoming regulatory interactions, off-treatment readouts and Phase III planning expected to shape the program’s next stage.
Scrip - April 21, 2026

Canada’s Jamp Deepens Immunology Biosimilars Push
Jamp Pharma has secured Health Canada approval for Upgolyv, a golimumab biosimilar to Simponi, expanding its Canadian immunology portfolio, strengthening its BioJamp division and advancing its strategy in high-growth specialty medicines.
Generics Bulletin - April 21, 2026

Xenon’s Azetukalner Confirms Phase III Efficacy Signal, Sets Up Mid-Year NDA Filing
Data from Xenon at the American Academy of Neurology meeting confirm azetukalner's Phase III efficacy in epilepsy ahead of a Q3 NDA filing.
Scrip - April 21, 2026

Argenx Shows Deepening Responses For Vyvgart Across The MG Spectrum
Data at the American Academy of Neurology support argenx’s bid to expand Vyvgart's reach in myasthenia gravis.
Scrip - April 21, 2026

AI Medtech Regulation In Limbo After EU Rules Simplification
The EU’s Digital Omnibus legislation delegates some AI medtech regulation to MDR – a role it is not necessarily built for.
Medtech Insight - April 21, 2026

AACR: Hansoh’s ADC Impresses In IO Combo For 2L NSCLC
Risvutatug rezetecan combined with adebrelimab, a PD-L1 antibody, scored a median progression-free survival of 14.0 months in a Phase I study for the second-line treatment of non-squamous non-small cell lung cancer without actionable genomic alterations.
Scrip - April 21, 2026

Graph Intelligence In Clinical Trials: Explainability Will Make Or Break It
In the first of an ongoing series of deep dives into biopharma-relevant AI topics, Norstella experts argue graph intelligence can untangle clinical trial fragmentation, if the results are explainable and GxP-compliant implementation discipline follows.
In Vivo - April 21, 2026

Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?
As Akeso’s ivonescimab emerges as a novel standard of care for certain non-small cell lung cancers in China, it might find itself going head-to-head with other anti-PD-(L)1/VEGF bispecifics emerging in the country.
Scrip - April 21, 2026

ACNU’s Simultaneous OTC/Rx Access Requirement Criticized By CHPA, PhRMA, Supported By AAM
Groups noted simultaneous OTC/Rx availability required for OTC switches approved through “additional conditions for nonprescription use” pathway in comments submitted in advance of meeting Duke-Margolis Institute for Health Policy conducts for FDA on April 23.
HBW Insight - April 21, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Icotyde could be J&J’s biggest ever product; daraxonrasib data boost Revolution; Travere’s Filspari becomes first drug for FSGS; GSK bets big on B7-H4 antibody-drug conjugate; and Lilly grabs top spot in global pharma sales.
Scrip - April 21, 2026